Why is the Licensed vs Unlicensed Point so Misunderstood with UK Medical Cannabis?

The conversation around medical cannabis in the UK is rife with confusion, especially regarding the distinction between licensed and unlicensed products. If you’ve ever read headlines proclaiming that medical cannabis is fully legal or that any doctor can prescribe it, you may have encountered some of the common misunderstandings that plague this topic. Terms like Class and Schedule are often mixed up, the changes introduced in November 2018 are misrepresented, and the limits on NHS access misunderstood.

In this post, we'll break down why the licensed vs lawful to prescribe point is so misunderstood, explain the legal framework governing medical cannabis, and clarify why NHS access remains limited despite the 2018 changes. Alongside, we'll naturally mention key players such as Nationwide Pharmacies, who specialise in supplying licensed and unlicensed medicines for medical cannabis patients.

Class vs Schedule: The Legal Foundations That Get Confused

One of the earliest points of confusion is the mixing up of Class and Schedule, two distinct legal classifications that govern cannabis and its derivatives in the UK.

What is Drug Classification by Class?

Drugs in the UK are divided into Classes A, B, and C under the Misuse of Drugs Act 1971. This classification relates to the potential harm and penalties for possession or trafficking:

Class A – highest risk (e.g., heroin, cocaine)
Class B – intermediate risk (includes cannabis)
Class C – lower risk (e.g., benzodiazepines)

Since cannabis remains a Class B drug, possession and supply are illegal except under tightly controlled medical exemptions.

What is Drug Scheduling?

Separately, Schedules under the Misuse of Drugs Regulations 2001 (updated in 2019) determine how and when controlled drugs can be prescribed and accessed in medical settings. There are five Schedules:

Schedule Main Characteristics Example Schedule 1 Mostly no recognised medical use; highly restricted MDMA, LSD Schedule 2 Medically used drugs requiring strict storage and prescription controls Morphine, cannabis-based products for medicinal use (CBPMs) Schedule 3 Medicines with less potential for dependence; fewer restrictions Barbiturates Schedule 4 Non-controlled drugs such as benzodiazepines (which are split further) Diazepam Schedule 5 Preparations with low strength controlled drugs; low risk Certain codeine preparations

Cannabis-based products prescribed for medical use are typically Schedule 2, reflecting strict regulation to prevent misuse while allowing medical access.

Why This Matters

Confusing Class and Schedule leads to claims like “medical cannabis is illegal” based on Class B status, ignoring the fact it can be prescribed under Schedule 2. Conversely, assuming Schedule 2 implies no legal restrictions is also wrong — the prescribing rules are tight. In short, the drugs remain criminalised under the 1971 Act as Class B, but some cannabis-based medicines are allowed in NHS or private care through Schedule 2 permissions.

Takeaway: Class relates to criminality and penalties, Schedule relates to medical prescribing controls — mixing these up fuels confusion in debates about medical cannabis legality.

What Changed in November 2018?

On 1 November 2018, a landmark reform allowed specialist doctors to prescribe cannabis-based products for medicinal use (CBPMs) in the UK, under very strict conditions.

The 2018 Amendment in Brief

Before Nov 2018, all cannabis was strictly prohibited for medical prescribing, classed as Schedule 1, meaning no medicinal use and no prescriptions allowed.
After the amendment, certain cannabis-based products were reclassified to Schedule 2, enabling specialist doctors to prescribe them under the usual controlled drug regulations.
The change acknowledged growing evidence of medical benefit in specific cases such as severe epilepsy, chemotherapy-induced nausea, and multiple sclerosis symptoms.

Important: This did not legalise medical cannabis in the sense that any doctor can prescribe it, nor did it remove the overarching prohibition under the 1971 Misuse of Drugs Act.

Why Has the Change Been Misunderstood?

The public and media headlines suggesting “medical cannabis is now legal” usually overlook that:

Only specialist consultants can prescribe, not GPs or any general practitioners.
Only licensed or specific unlicensed cannabis-derived medicinal products can be prescribed - the vast majority of products remain unlicensed.
The products require a special prescription and adherence to Schedule 2 regulations.

Hence, even with the 2018 change, medical cannabis remains rare and tightly controlled. Nationwide Pharmacies, for example, specialise in navigating the complex requirements to supply both licensed and unlicensed cannabis medicines legally to patients under specialist prescription.

Takeaway: The November 2018 reform allowed limited medical prescribing under strict controls — it was not a full legalisation or broad NHS access.

Why Cannabis Remains Illegal Under the 1971 Act

The Misuse of Drugs Act 1971 still classifies cannabis as a Class B drug, meaning its possession, cultivation, and supply are criminal offences for non-exempted uses. This remains the fundamental legal barrier that confuses many.

The Root of the Conflict

The 1971 Act focuses on preventing drug misuse and harm and controls substances accordingly.
The law has limited flexibility; even with medical advances, cannabis is still categorised alongside harmful recreational drugs.
The 2018 amendment did not repeal or replace the 1971 Act; it amended the Misuse of Drugs Regulations 2001 instead, which governs medical prescribing procedures and drug scheduling.

Consequences for Patients and Prescribers

This means that any medical use authorized under Schedule 2 is essentially an “exception to the rule” permitted by regulatory amendments but does not represent a fundamental change in the drug’s class status. The 1971 Act criminal provisions still apply to unauthorised possession and supply.

Therefore, claims that “medical cannabis is legal” overlook the fact that all possession outside specialist prescribing remains criminal. It also explains why NHS access is limited: the 1971 Act provides the overarching context for caution, affecting policy and practice.

Takeaway: Cannabis remains illegal as a Class B drug under the 1971 Act — the medical prescribing framework is a narrow regulated exception, not a broad legalisation.

Specialist-Only Prescribing and Why NHS Access Is Limited

Since 2018, only specialist doctors on the General Medical Council's specialist register can prescribe cannabis-based medicines for medicinal use. This restricts NHS access considerably.

Why Only Specialists?

Medical cannabis requires detailed clinical assessment to weigh benefits against potential risks like dependency or side effects.
Specialists in neurology, pain management, or palliative care are better placed to prescribe appropriate cannabis products given the limited licensed options.
The National Institute for Health and Care Excellence (NICE) has not generally endorsed broad use of medical cannabis due to limited robust evidence, so NHS guidelines urge caution.

Why Is NHS Access So Limited?

NHS prescribing of medical cannabis is subject to stringent clinical commissioning policies. Most prescriptions are currently issued privately or via specialist clinics rather than routinely on the NHS. This is because:

Limited licensed products: There are very few cannabis medicines with full marketing authorisation in the UK, which limits NHS procurement and prescribing.
Cost and policy caution: NHS bodies require strong evidence and cost-effectiveness before funding cannabis medicines, which is often lacking.
Unlicensed medicines UK framework: When there’s no licensed product, clinicians can prescribe unlicensed medicines (i.e., those without formal marketing authorisation but clinically necessary). Nationwide Pharmacies is one such supplier that provides both licensed and unlicensed cannabis medicines to patients under these specialist prescriptions.

The term marketing authorisation confusion also arises here: licensed medicines have formal approval for specific indications, but unlicensed medicines can be prescribed off-label or when no licensed alternative exists — under specialist supervision and with patient consent.

Takeaway: NHS access to medical cannabis is limited because only specialists can prescribe, and the majority of cannabis medicines remain unlicensed or lack full NHS endorsement.

Understanding Licensed vs Lawful to Prescribe and Unlicensed Medicines UK

What Does “Licensed” Mean?

A licensed medicine is one that has obtained marketing authorisation (licence) from the Medicines and Healthcare products Regulatory Agency (MHRA). This authorisation means the drug has met standards for safety, efficacy, and quality for specific indications.

For medical cannabis, licensed products are rare but include Epidyolex (a CBD-based medicine for epilepsy), which has full MHRA approval.

What About Unlicensed Medicines?

Many cannabis products prescribed in the UK are unlicensed medicines. These medicines lack formal marketing authorisation for their specific use or composition but may be prescribed where licensed options are unavailable or unsuitable.

Unlicensed prescribing must be done by specialists experienced in the area, with clearly documented clinical rationale and informed patient consent. Suppliers like Nationwide Pharmacies specialise in the legal distribution of these unlicensed cannabis medicines according to regulatory frameworks.

Why the Marketing Authorisation Confusion?

Confusion arises when people equate “licensed” with “legal to prescribe” or “safe”. In reality:

Licensed medicines have marketing authorisation for specific uses but are not always available or appropriate for every patient.
Unlicensed medicines can still be lawfully prescribed under specialist supervision.
Marketing authorisation status does not affect the drug’s class under the 1971 Act or its scheduling under the Misuse of Drugs Regulations.

Understanding this distinction is key to interpreting the UK medical cannabis landscape accurately.

Final takeaway: Licensed status refers to marketing authorisation — lawful prescribing can also apply to unlicensed medicines under strict specialist conditions, especially relevant to medical cannabis.

Summary: Clearing the Smoke Around UK Medical Cannabis Legalities

Class B drug status under the 1971 Misuse of Drugs Act means cannabis remains illegal except under very restricted medical exemptions.
Schedules 1 and 2 govern whether cannabis products can be prescribed; since Nov 2018, certain cannabis-based products are Schedule 2, allowing prescription by specialist doctors only.
Only specialists on the GMC register can prescribe cannabis medicines — GPs cannot prescribe them routinely, which limits NHS access.
Medical cannabis products are mostly unlicensed medicines in the UK, which can be lawfully prescribed under specialist guidance with informed consent.
Marketing authorisation confusion causes misunderstanding: licensed products have MHRA approval, unlicensed do not, but both can be prescribed lawfully.
Nationwide Pharmacies and similar specialist suppliers play a key role in legally supplying licensed and unlicensed cannabis medicines within UK regulation.

In conclusion, understanding the legal framework — proper distinctions between Class and Schedule, the crucial 2018 regulatory change, and the difference between licensed and unlicensed medicines — is essential. It dispels misleading claims and clarifies why medical cannabis remains https://www.tntmagazine.com/leisure-entertainment/leisure/why-is-cannabis-still-illegal-in-the-uk-the-history-behind-medical-cannabis-law/ a specialist-only, limited-access treatment in the UK.